Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.

Concentration-controlled everolimus with reduced CsA results in similar renal function and equivalent efficacy compared with MMF with standard CsA at 12 months after cardiac transplantation.